Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy

Purpose: HER2-positive breast cancer (BC) achieving pathological complete remission (pCR) after neoadjuvant therapy (NAT) had a superior disease outcome. Dysmetabolism and stimulation of insulin-like growth factor 1 (IGF-1)-axis would increase BC risk, but we are lacking data for their association w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Yi-Wei, Wang, Gen, Wu, Jia-Yi, Huang, Ou, He, Jian-Rong, Zhu, Li, Chen, Wei-Guo, Li, Ya-Fen, Chen, Xiao-Song, Shen, Kun-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535081/
https://www.ncbi.nlm.nih.gov/pubmed/31190894
http://dx.doi.org/10.2147/OTT.S194981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535081/
https://www.ncbi.nlm.nih.gov/pubmed/31190894
http://dx.doi.org/10.2147/OTT.S194981

Ejemplares similares